Results 11 to 20 of about 24,300 (246)

The role of extracellular vesicles in chronic lung allograft dysfunction and response to extracorporeal photopheresis. [PDF]

JHLT Open
Current research highlights the growing role of extracellular vesicles (EV) in mechanisms of lung allograft dysfunction. In particular, EVs are involved in antigen presentation, where they are released from lung allografts and express tissue associated ...
Crossland RE, Bolton SJ, Fisher AJ.
europepmc   +5 more sources

Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction [PDF]

Scientific Reports, 2021
AbstractChronic Lung Allograft Dysfunction (CLAD), manifesting as Bronchiolitis Obliterans Syndrome (BOS) or Restrictive Allograft Syndrome (RAS), is the main reason for adverse long-term outcome after Lung Transplantation (LTX). Until now, no specific biomarkers exist to differentiate between CLAD phenotypes.
Cecilia Veraar, Jonathan Kliman, Alberto Benazzo, Felicitas Oberndorfer, Maria Laggner, Philipp Hacker, Thomas Raunegger, Stefan Janik, Peter Jaksch, Walter Klepetko, Hendrik J. Ankersmit, Bernhard Moser   +11 more
openaire   +3 more sources

Influence of mycophenolate mofetil dosage and plasma levels on the occurrence of chronic lung allograft dysfunction in lung transplants: a retrospective cohort analysis [PDF]

Swiss Medical Weekly, 2022
INTRODUCTION: Development of chronic lung allograft dysfunction is a limiting factor for post-lung transplant survival. We evaluated whether the dose of the immunosuppressant mycophenolate mofetil or plasma concentrations of the active metabolite ...
Gaisl, Thomas, Gautschi, Fiorenza, Hage, René, Ortmanns, Gernot, Saurer, Philipp, Schuurmans, Macé M, Steinack, Carolin   +6 more
core   +4 more sources

Outcomes Following ATG Therapy for Chronic Lung Allograft Dysfunction

Transplantation Direct, 2021
Background. Chronic lung allograft dysfunction (CLAD) is the major factor limiting survival post lung transplantation (LTx) with limited effective therapeutic options. We report our 12-y experience of antithymocyte globulin (ATG) as second-line CLAD therapy. Methods.
Sakhee Kotecha, FRACP, Eldho Paul, BS, MS, Steve Ivulich, MPharm, Jeremy Fuller, BS, Miranda Paraskeva, FRACP, Bronwyn Levvey, RN, Gregory Snell, MD, FRACP, Glen Westall, PhD, FRACP   +7 more
openaire   +4 more sources

Lung retransplantation for chronic lung allograft dysfunction

Polish Journal of Cardio-Thoracic Surgery, 2019
Monika Kosiorowska, Bartosz Kubisa, Mikołaj Górski, Maria Piotrowska, Michał Kubisa, Mirosław Brykczyński, Małgorzata Wojtyś, Jarosław Pieróg, Michalina Czarnecka, Janusz Wójcik, Norbert Wójcik, Michał Bielewicz, Piotr Sielicki, Tomasz Grodzki   +13 more
openaire   +4 more sources

Update on the immunological mechanisms of primary graft dysfunction and chronic lung allograft dysfunction. [PDF]

Curr Opin Organ Transplant
Jeong JC, Gelman AE, Chong AS.
europepmc   +3 more sources

Increase in Alveolar Septal Width Is a Histological Predictor of Chronic Lung Allograft Dysfunction and Survival in Lung Transplant Recipients-A Longitudinal Study. [PDF]

J Clin Med
Kuhnert S, Rotert AM, Sommerlad J, Yogeswaran A, Reichert M, Askevold I, Hecker A, Koch C, Bräuninger A, Gattenlöhner S, Seeger W, Hecker M, Dorfmüller P.   +12 more
europepmc   +3 more sources

Radiological distribution patterns in restrictive chronic lung allograft dysfunction: Impact on survival across all phenotypes. [PDF]

JHLT Open
Fukuda T, Nakamura Y, Tseng SC, Ko Y, Gagne SM, Johkoh T, Li Y, Christiani DC, Ojiri H, Sholl L, Nishino M, Hatabu H.   +11 more
europepmc   +2 more sources

Chronic lung allograft dysfunction after lung transplantation: prevention, diagnosis and treatment in 44 European centres. [PDF]

ERJ Open Res
Gottlieb J, Vos R, Jaksch P, Hellemons M, Holm AM, Morlacchi LC, Magnusson J, Alonso Moralejo R, Mora-Cuesta VM, Ennekes V, Reed A, Merveilleux Du Vignaux C, Hettich I, Bennett D, Hecker M, Wald A, Guk S, Skride A, Nolde A, Knoop C, Meloni F, Tikkanen J, Larsson H, Tissot A, Riddell P, Le Pavec J, Perch M, Renaud-Picard B, Carlier FM, Müller V, Parmar J, Havlin J, Laporta R, Schuurmans MM, Harlander M, Zenglen S, Brugiere O, Kneidinger N, Fisher A, Saez-Gimenez B.   +39 more
europepmc   +2 more sources

Plasma Cell-free DNA Associated With Risk of Mortality and Chronic Lung Allograft Dysfunction Among Lung Transplant Recipients With <i>Aspergillus</i>. [PDF]

Transplant Direct
Background. Aspergillus species is a common pathogen in lung transplant patients. However, existing clinical standards rely on a complex constellation of clinical, radiological, and microbiologic criteria with limited sensitivity to differentiate between
Hamad Y, Mathew J, Andargie T, Nathan SD, Kong H, Jang MK, Shah P, Aryal S, Agbor-Enoh S.   +8 more
europepmc   +2 more sources